Umecrine Cognition Overview
- Founded
-
2006
- Status
-
Private
- Employees
-
3
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$4.1M
- Investors
-
5
Umecrine Cognition General Information
Description
Developer of pharmaceutical products designed to treat cognitive neurological disorders. The company's pharmaceutical products focus on finding treatments for neurological disorders in the central nervous system that are caused by endogenous CNS-active steroids (GABA-steroids), enabling healthcare industries to provide treatment that directly addresses the neurocognitive signs and symptoms of Hepatic encephalopathy.
Contact Information
Website
www.umecrinecognition.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- Karolinska Institutet Science Park
- Fogdevreten 2
- 171 65 Solna
- Sweden
+46 073-039 00 00
Umecrine Cognition Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 14-Jul-2021 | $4.1M | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 3. Later Stage VC | 04-Oct-2017 | 00.000 | 00.000 | Completed | Clinical Trials - Phase 2 | |
| 2. Later Stage VC | 22-Nov-2016 | $4.96M | $4.96M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC | Completed | Startup |
Umecrine Cognition Patents
Umecrine Cognition Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3083555-A1 | Pharmaceutical formulation of 3.alpha.-ethynyl-3.beta.-hydroxyandrostan-17-one oxime | Pending | 27-Nov-2017 | 0000000000 | |
| AU-2018374029-A1 | Pharmaceutical formulation of 3a-ethynyl-3b-hydroxyandrostan-17-one oxime | Pending | 27-Nov-2017 | 0000000000 | |
| US-20190358244-A1 | Pharmaceutical formulation of 3alpha -ethynyl-3beta-hydroxyandrostan-17-one oxime | Granted | 27-Nov-2017 | 0000000000 | |
| JP-2021504468-A | Pharmaceutical formulation of 3α-ethynyl-3β-hydroxyandrostane-17-onoxime | Pending | 27-Nov-2017 | 0000000000 | |
| US-11123351-B2 | Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime | Active | 27-Nov-2017 | A61K9/4858 |
Umecrine Cognition Executive Team (5)
Umecrine Cognition Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bruce Scharschmidt Ph.D | Umecrine Cognition | Board Member | 000 0000 |
| John Öhd Ph.D | Karolinska Development | Board Member | 000 0000 |
| Kenth Bergström | Self | Board Member | 000 0000 |
| Thomas Blackburn Ph.D | Umecrine Cognition | Board Member | 000 0000 |
| Torbjörn Bäckström MD | Umecrine Cognition | Founder, Co-Chief Executive Officer & Board Member | 000 0000 |
Umecrine Cognition Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Umecrine Cognition Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Almi Invest | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Fort Knox Förvaring | Holding Company | Minority | 000 0000 | 000000 0 | |
| Karolinska Development | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Norrlandsfonden | Lender/Debt Provider | Minority | 000 0000 | 000000 0 | |
| Partnerinvest Norr | Venture Capital | Minority | 000 0000 | 000000 0 |